Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | ||||||||
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 5, 2025
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s Telephone Number, Including Area Code: (317 ) 276-2000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Eli Lilly and Company (the “Company”) annual meeting of shareholders (the “2025 Annual Meeting”) was held on May 5, 2025. The total number of shares of the Company's common stock voted in person or by proxy at the 2025 Annual Meeting was 846,655,979, representing approximately 89% of the 947,989,151 shares that were outstanding and entitled to vote as of February 26, 2025, the record date of the 2025 Annual Meeting. Voting results for each matter submitted to a vote at the 2025 Annual Meeting are provided below.
a) The four nominees for director were elected to serve three-year terms ending at the Company's annual meeting of shareholders in 2028, as follows:
| Nominee | For | Against | Abstain | Broker Nonvote | ||||||||||
| Ralph Alvarez | 724,174,318 | 36,267,076 | 725,465 | 85,489,120 | ||||||||||
| Mary Lynne Hedley | 754,599,984 | 5,904,923 | 661,952 | 85,489,120 | ||||||||||
| Kimberly Johnson | 756,799,570 | 3,694,183 | 673,106 | 85,489,120 | ||||||||||
| Juan Luciano | 726,529,639 | 33,547,286 | 1,089,934 | 85,489,120 | ||||||||||
b) By the following vote, the shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers:
| For | Against | Abstain | Broker Nonvote | ||||||||
| 731,376,577 | 28,008,877 | 1,781,405 | 85,489,120 | ||||||||
c) The appointment of Ernst & Young LLP as the Company's independent auditor for 2025 was ratified by the following shareholder vote:
| For | Against | Abstain | ||||||
| 805,143,438 | 40,773,622 | 738,919 | ||||||
d) The proposal to amend the Company's Articles of Incorporation (the “Articles”) to eliminate the classified board structure did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows:
| For | Against | Abstain | Broker Nonvote | ||||||||
| 658,827,716 | 100,815,677 | 1,523,466 | 85,489,120 | ||||||||
e) The proposal to amend the Articles to eliminate supermajority voting provisions did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows:
| For | Against | Abstain | Broker Nonvote | ||||||||
| 655,797,749 | 103,931,990 | 1,437,120 | 85,489,120 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ELI LILLY AND COMPANY | ||||||||
| (Registrant) | ||||||||
| By: | /s/ Anat Hakim | |||||||
| Name: | Anat Hakim | |||||||
| Title: | Executive Vice President, General Counsel and Secretary | |||||||
| Date: | May 8, 2025 | |||||||